# Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma

> **NCT03857815** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **RADIATION:** anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT03857815
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-25
- **Primary completion:** 2020-09-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03857815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03857815, "Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT03857815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*